رونوشت 🔗
1
00:00:00,790 --> 00:00:06,939
Episode 435, "Optimized Pharmacy
Benefits Are Required If You Want
2
00:00:06,939 --> 00:00:09,419
to Do or Buy value-based Care".
3
00:00:09,610 --> 00:00:11,911
Today, I speak with Dan Mendelson.
4
00:00:19,892 --> 00:00:23,660
American Healthcare Entrepreneurs and
Executives You Want to Know Talking.
5
00:00:26,380 --> 00:00:28,109
Relentlessly Seeking Value.
6
00:00:28,619 --> 00:00:34,099
This conversation I am having with Dan
Mendelson, my guest today, all started
7
00:00:34,160 --> 00:00:38,390
with a post that he had written on
LinkedIn considering how pharmacy
8
00:00:38,390 --> 00:00:43,070
benefits can or should be optimized within
the broader context of value-based care.
9
00:00:43,570 --> 00:00:47,480
Total cost of care, value-based
medical care, and pharmacy benefits.
10
00:00:47,540 --> 00:00:49,570
These worlds have to collide.
11
00:00:49,670 --> 00:00:53,559
There is just so much intertwined into
all of this, which is why I pretty much
12
00:00:53,560 --> 00:00:57,319
immediately invited him to come back on
the pod to discuss in greater detail.
13
00:00:57,419 --> 00:01:00,719
A few years ago, I heard a doctor
say that practicing medicine without
14
00:01:00,719 --> 00:01:04,309
considering pharmacy is like getting
to the 90 yard line, putting down
15
00:01:04,309 --> 00:01:05,889
the ball, and walking off the field.
16
00:01:06,089 --> 00:01:09,509
And yeah, when a patient gets to
a certain point in a whole lot
17
00:01:09,519 --> 00:01:13,919
of disease progressions, optimal
medical therapy includes pharmacy.
18
00:01:14,019 --> 00:01:14,719
It's a thing.
19
00:01:14,879 --> 00:01:16,379
Adherence is a thing.
20
00:01:16,609 --> 00:01:19,819
In fact, I saw a stat the other
day that patients not taking
21
00:01:19,829 --> 00:01:26,819
their meds cost an estimated
$3,874 PEPY per employee per year.
22
00:01:27,009 --> 00:01:31,429
Also half of all hospital admits
are caused by non-adherence.
23
00:01:31,649 --> 00:01:35,749
Those two stats, by the way, are from
a post on LinkedIn by Brian Bellware,
24
00:01:35,769 --> 00:01:38,139
who was recapping a video from Dr.
25
00:01:38,149 --> 00:01:39,089
Eric Bricker.
26
00:01:39,159 --> 00:01:40,189
Link in the show notes.
27
00:01:40,419 --> 00:01:44,629
But also, as Barbara Wachsman said
on the show, half, I think she
28
00:01:44,629 --> 00:01:48,759
said, of all ER visits are due to
patients not taking their meds right.
29
00:01:48,789 --> 00:01:51,609
Olivia Webb was on the pod, if you
want to go back and listen to that
30
00:01:51,609 --> 00:01:55,279
one, talking about how she spends
hours every month trying to figure
31
00:01:55,279 --> 00:02:00,199
out how to navigate access issues to
manage to get her Crohn's disease drug.
32
00:02:00,449 --> 00:02:04,489
So yeah, one underlying reason
why a lot of this stuff happens
33
00:02:04,529 --> 00:02:08,209
is that pharmacy benefits are
purchased and siloed a lot of times.
34
00:02:08,464 --> 00:02:13,034
In fact, I have yet to see, really,
any mainstream contract wherein a
35
00:02:13,084 --> 00:02:18,374
PBM is held accountable in any way
for downstream medical costs, which
36
00:02:18,454 --> 00:02:22,574
may be incurred because of suboptimal
pharmacy benefit design, right?
37
00:02:22,574 --> 00:02:25,904
And there are so many examples of
bad downstream medical impacts.
38
00:02:26,079 --> 00:02:27,440
I really like how Dr.
39
00:02:27,480 --> 00:02:29,870
Mark Fendrick put it in episode 308.
40
00:02:30,529 --> 00:02:35,566
He said benefits, including pharmacy
benefits, are like peanut butter and jelly
41
00:02:35,596 --> 00:02:38,106
relative to enabling high quality care.
42
00:02:38,596 --> 00:02:44,516
You gotta have both working in concert,
like CMS or a plant sponsor just paid a
43
00:02:44,546 --> 00:02:49,236
ton of money to get a patient an organ
transplant, and then the patient can't
44
00:02:49,236 --> 00:02:53,466
afford their transplant meds, which aren't
on formulary and are really expensive,
45
00:02:53,486 --> 00:02:55,636
and therefore there's organ rejection.
46
00:02:55,716 --> 00:02:56,766
This happens.
47
00:02:57,006 --> 00:03:02,036
Or a patient with uncontrolled diabetes
with a huge co pay for insulin, doctor
48
00:03:02,036 --> 00:03:03,866
says, hey, you gotta take your insulin.
49
00:03:04,081 --> 00:03:05,821
Patient says, can't afford it, right?
50
00:03:05,891 --> 00:03:08,611
Like this makes no sense,
and it's shockingly common.
51
00:03:08,811 --> 00:03:12,811
I'm thinking right now of that young
man who died in the Midwest because
52
00:03:12,811 --> 00:03:14,821
he could not get his asthma inhaler.
53
00:03:14,821 --> 00:03:15,981
It wasn't on formulary.
54
00:03:16,191 --> 00:03:17,431
So here's the game plan.
55
00:03:17,591 --> 00:03:22,531
I talk with Dan about the five kind of
vital considerations he had brought up
56
00:03:22,541 --> 00:03:26,771
in that aforementioned LinkedIn post
when considering how pharmacy benefits
57
00:03:26,771 --> 00:03:30,971
can or should be optimized within the
broader context of value-based care.
58
00:03:31,216 --> 00:03:35,406
Dan's advice for the pharma
industry are woven in here as much
59
00:03:35,406 --> 00:03:39,626
as his advice for EBC's employee
benefit consultants and employers.
60
00:03:39,816 --> 00:03:43,876
I am sure that most of our listeners
are going to be very familiar with
61
00:03:43,926 --> 00:03:47,506
Dan Mendelson, my guest today, and
his work, but the quick background
62
00:03:47,516 --> 00:03:49,546
here is that he runs Morgan Health.
63
00:03:49,846 --> 00:03:53,856
The mission over there at Morgan Health
is to drive innovation in employer
64
00:03:53,856 --> 00:03:58,076
sponsored health care, and they do that by
investing and working with their portfolio
65
00:03:58,076 --> 00:04:04,376
companies in the context of the 300,000
or so employees over at JPMorgan Chase.
66
00:04:04,636 --> 00:04:08,956
At the same time, Morgan Health
Load full transcript
also engages in policy discussions
67
00:04:08,956 --> 00:04:13,596
because, as Dan says, no one employer
is going to control public policy.
68
00:04:13,841 --> 00:04:18,871
As a footnote here, I just will say
that I actively seek out opportunities
69
00:04:18,871 --> 00:04:21,361
to listen to Dan Mendelson's thoughts.
70
00:04:21,531 --> 00:04:25,011
He has spoken a lot and really
eloquently and with great insight
71
00:04:25,031 --> 00:04:28,681
about setting up the economic models
for healthcare, not sick care.
72
00:04:28,821 --> 00:04:32,061
Recently, actually, he was on a
panel at the Milken conference.
73
00:04:32,286 --> 00:04:34,436
Along with Natalie Davis, Dr.
74
00:04:34,436 --> 00:04:36,216
Yele Aluko, and Dr.
75
00:04:36,256 --> 00:04:39,596
Henry Ting, there are definitely
insights to be gleaned.
76
00:04:39,596 --> 00:04:42,526
I will link to that panel
discussion in the show notes.
77
00:04:42,656 --> 00:04:43,856
My name is Stacey Richter.
78
00:04:43,876 --> 00:04:46,676
This podcast is sponsored
by Aventria Health Group.
79
00:04:46,856 --> 00:04:48,936
Dan Mendelson, welcome to
Relentless Health Value.
80
00:04:49,086 --> 00:04:50,336
Great to be here, Stacey.
81
00:04:50,586 --> 00:04:53,456
The conversation that I would really
like to have today is connecting the
82
00:04:53,456 --> 00:04:59,996
dots between value-based medical care
and then the buying of pharmacy benefits.
83
00:05:00,236 --> 00:05:04,296
What are your thoughts maybe on how
these worlds collide, the pharmacy
84
00:05:04,296 --> 00:05:05,546
world and then the medical side?
85
00:05:05,836 --> 00:05:10,056
Well, look, value-based care is
fundamental to everything that we
86
00:05:10,056 --> 00:05:11,686
are doing here at Morgan Health.
87
00:05:11,886 --> 00:05:15,946
We believe our employees and
their dependents need to get
88
00:05:15,946 --> 00:05:18,406
high quality and affordable care.
89
00:05:18,586 --> 00:05:22,956
It really starts with having a clinical
team that will help guide you and
90
00:05:23,166 --> 00:05:27,466
having a tool set so that you can
be guided in a way that makes sense.
91
00:05:27,516 --> 00:05:29,816
Pharmacy has to do the same thing.
92
00:05:29,926 --> 00:05:32,826
I mean, it has to be
accessible to employees.
93
00:05:33,301 --> 00:05:39,591
It has to be managed by a clinical
team and it has to be integrated into
94
00:05:39,631 --> 00:05:41,391
the overall context of their care.
95
00:05:41,781 --> 00:05:47,021
When you say managed by a clinical team,
so you mean that the formulary development
96
00:05:47,071 --> 00:05:48,841
needs to be managed by a clinical team?
97
00:05:48,861 --> 00:05:50,391
Is that your point there?
98
00:05:50,806 --> 00:05:54,866
It's not just the formulary, so
when you are prescribed a medicine,
99
00:05:54,906 --> 00:05:59,366
we want that medicine to be the
appropriate and rational medicine
100
00:05:59,366 --> 00:06:01,266
in the context of your condition.
101
00:06:01,606 --> 00:06:05,466
And
we want it to be prescribed in
as cost effective way as possible.
102
00:06:05,466 --> 00:06:09,166
So that becomes a target, you know,
if you think about value-based care,
103
00:06:09,236 --> 00:06:12,836
if you're improving the affordability
of care, you're improving the value.
104
00:06:13,336 --> 00:06:16,286
You had written a post the other day
on LinkedIn, which I thought was super
105
00:06:16,316 --> 00:06:22,166
interesting because it hits this middle
ground that I think isn't explored a lot.
106
00:06:22,341 --> 00:06:25,781
It's this middle ground between
how does medical care improve if
107
00:06:25,791 --> 00:06:27,381
pharmacy benefits are done well?
108
00:06:27,431 --> 00:06:31,191
Which sounds obvious on the face
of it, just to say, but it really,
109
00:06:31,191 --> 00:06:32,891
we don't talk about it a lot.
110
00:06:33,751 --> 00:06:37,781
I'd say one of the biggest problems
that we have is that for most employers,
111
00:06:37,851 --> 00:06:42,551
the pharmacy benefit is really
divorced from the medical benefit.
112
00:06:42,571 --> 00:06:45,371
They are two separate things,
and they're really not being
113
00:06:45,601 --> 00:06:48,391
considered or managed together.
114
00:06:48,781 --> 00:06:49,131
Yeah.
115
00:06:49,131 --> 00:06:54,791
And in their defense, the whole way
that even data is collected, just the
116
00:06:54,801 --> 00:06:59,691
framework, the buying, the everything
is, is so completely separate.
117
00:07:00,191 --> 00:07:01,591
You have the incentives.
118
00:07:01,611 --> 00:07:05,731
Like if you've got a pharmacy vendor
who's thinking to themselves, well, my
119
00:07:05,731 --> 00:07:08,041
job here is to reduce pharmacy spend.
120
00:07:08,541 --> 00:07:13,741
Then they're going to do reducing pharmacy
spend kind of things, even if those
121
00:07:13,751 --> 00:07:15,921
same things increase medical spending.
122
00:07:15,981 --> 00:07:19,381
That system is increasingly
difficult to swallow.
123
00:07:19,431 --> 00:07:24,791
Look, you do have systems, and again,
I go back to Kaiser as my example of
124
00:07:24,871 --> 00:07:29,221
a highly managed system where pharmacy
and medical are truly integrated.
125
00:07:29,606 --> 00:07:33,136
But you do have systems where things
are integrated and when you look
126
00:07:33,136 --> 00:07:36,846
at those systems, when you analyze
those systems, you see better generic
127
00:07:36,846 --> 00:07:41,396
utilization, you see more drugs
being prescribed in general and more
128
00:07:41,466 --> 00:07:43,656
affordable drugs being prescribed.
129
00:07:43,776 --> 00:07:48,496
We think about where things need to go for
an employer and the work that we're doing
130
00:07:48,496 --> 00:07:54,636
right now in Columbus, Ohio with APRI, we
have primary care clinics in the worksite.
131
00:07:54,826 --> 00:07:58,186
And the drug spend needs to be integrated.
132
00:07:58,276 --> 00:08:05,986
You had written there are five points
any plan sponsor might want to consider
133
00:08:05,986 --> 00:08:09,916
if they're interested in making
pharmacy benefit decisions that are
134
00:08:09,946 --> 00:08:14,786
wise from both the plan standpoint,
but then also a win-win with members
135
00:08:14,816 --> 00:08:18,076
that actually enable members to get,
you know, the best possible health
136
00:08:18,086 --> 00:08:21,546
that they can and also align with
value-based goings on elsewhere.
137
00:08:21,726 --> 00:08:24,246
So I really want to go through
these five points because I think
138
00:08:24,256 --> 00:08:26,716
they sum up a lot of wisdom.
139
00:08:27,106 --> 00:08:31,916
The first one that you offered was to
have some kind of value-based component
140
00:08:31,946 --> 00:08:33,576
in the decision making process.
141
00:08:33,736 --> 00:08:36,996
One of the things that I would just
say is that you can't do whole person
142
00:08:36,996 --> 00:08:40,716
health if we're making it really hard for
someone to get a drug that they need or
143
00:08:40,716 --> 00:08:42,226
stay adherent to a drug that they need.
144
00:08:42,371 --> 00:08:46,221
So your first point was to have
some kind of value-based component
145
00:08:46,241 --> 00:08:47,711
in the decision making process.
146
00:08:47,741 --> 00:08:49,511
How do you think about that?
147
00:08:50,141 --> 00:08:54,871
Well, the most important starting
point is when the physician prescribes
148
00:08:54,871 --> 00:08:56,261
a medication to the patient.
149
00:08:56,351 --> 00:09:02,511
If she starts with a cost effective
generic medication, we will get
150
00:09:02,531 --> 00:09:04,151
a more cost effective solution.
151
00:09:04,521 --> 00:09:08,551
If she decides to go immediately
to the most expensive brand of
152
00:09:08,551 --> 00:09:10,195
medication, you will never go back.
153
00:09:10,255 --> 00:09:14,225
And then I'd say also kind of a second
point here is that physicians often
154
00:09:14,255 --> 00:09:20,045
prescribe ignorant of the formulary that
the patient faces and the prescribing
155
00:09:20,055 --> 00:09:24,694
has to be done in consultation with
the formulary that the patient faces.
156
00:09:25,090 --> 00:09:25,500
All right.
157
00:09:25,620 --> 00:09:27,600
So many questions, so little time.
158
00:09:27,890 --> 00:09:31,030
I know that every doctor listening
right now, so I'm just going to hit the
159
00:09:31,030 --> 00:09:35,010
last one first, is like, I don't even
know what insurance my patient has.
160
00:09:35,070 --> 00:09:38,110
And even if I did with
all the carve outs, right?
161
00:09:38,110 --> 00:09:39,720
So like, oh, they have
Blue Cross Blue Shield.
162
00:09:39,910 --> 00:09:40,610
Fantastic.
163
00:09:40,610 --> 00:09:43,749
Except there's some employer carve
out that affects the formulary.
164
00:09:43,970 --> 00:09:46,990
So how do I even know
what this formulary is?
165
00:09:47,000 --> 00:09:52,160
How do you enable the information
that's necessary at the point of care
166
00:09:52,179 --> 00:09:54,260
to be able to do
something like that?
167
00:09:54,790 --> 00:10:00,610
This is one of the many reasons why
a tightly managed environment can be
168
00:10:00,610 --> 00:10:04,980
better for the patient financially
because the physician actually does
169
00:10:05,040 --> 00:10:07,250
know their way around the formulary.
170
00:10:07,349 --> 00:10:11,620
I think that particularly when it
comes to very expensive medications
171
00:10:12,499 --> 00:10:15,720
it is incumbent on the physician
to understand the financial
172
00:10:15,730 --> 00:10:17,300
situation that the patient faces.
173
00:10:17,480 --> 00:10:20,680
And by the way, it's also
associated with adherence.
174
00:10:20,940 --> 00:10:25,780
So if you prescribe a drug that
is way expensive for the patient,
175
00:10:25,780 --> 00:10:28,915
they are much less likely to
fill it and to keep taking it.
176
00:10:29,235 --> 00:10:31,955
When you say a tightly managed
environment, what does that mean?
177
00:10:31,965 --> 00:10:35,205
It means Kaiser, you know, or
something similar to Kaiser.
178
00:10:35,235 --> 00:10:37,774
There are really interesting
startup companies.
179
00:10:37,775 --> 00:10:43,025
One of them is a company that we invested
in, Centivo, that offers a tightly
180
00:10:43,025 --> 00:10:48,255
managed product for employed populations
in places where Kaiser doesn't operate.
181
00:10:48,385 --> 00:10:49,985
It's a managed network.
182
00:10:49,995 --> 00:10:54,355
So it's a narrow network product,
and it's a formulary that is
183
00:10:54,355 --> 00:10:55,905
calibrated to cost effectiveness.
184
00:10:56,330 --> 00:11:01,520
We had Ashok Subramanian, who's the CEO of
Centivo on the show a couple of years ago.
185
00:11:01,730 --> 00:11:06,950
So the point that you're making is
to have an entity wherein patients
186
00:11:06,950 --> 00:11:14,570
are navigated to high value providers
who have proven their adeptness at
187
00:11:14,580 --> 00:11:18,930
delivering patient care that's both
affordable as well as high quality.
188
00:11:19,180 --> 00:11:22,540
Yes, and I'll make the additional
point that many payviders just
189
00:11:22,550 --> 00:11:24,120
haven't gotten to pharmacy yet.
190
00:11:24,350 --> 00:11:28,120
They need to, because it's 25 percent
of the expense for the employer.
191
00:11:28,640 --> 00:11:33,339
And so when you think about
managing cost effectiveness, they
192
00:11:33,340 --> 00:11:35,630
have to be dipping into that.
193
00:11:35,640 --> 00:11:40,240
And look, we're also looking at
a world where increasingly the
194
00:11:40,250 --> 00:11:41,910
cost of medications are going up.
195
00:11:42,010 --> 00:11:43,750
The pipeline is unbelievable.
196
00:11:43,820 --> 00:11:47,400
I mean, think about the, the
GLP-1s are incredible technology.
197
00:11:47,615 --> 00:11:49,685
They also come at an incredible cost.
198
00:11:49,685 --> 00:11:53,245
I mean, we're looking at data that
shows that some employers are spending
199
00:11:53,275 --> 00:11:57,445
up to 2 percent of
their pharmacy
benefit right now on GLP-1s alone.
200
00:11:57,764 --> 00:11:59,395
That's not tenable in the long term.
201
00:11:59,565 --> 00:12:03,674
You think about cell and gene
therapy, therapies for sickle
202
00:12:03,675 --> 00:12:06,145
cell and other genetic diseases.
203
00:12:06,480 --> 00:12:09,710
Those therapies are going to
come to market with price tags
204
00:12:09,710 --> 00:12:13,500
between two and a half and 5
million dollars per application.
205
00:12:13,900 --> 00:12:16,729
And employers are going to have to
figure out how to deal with that.
206
00:12:16,739 --> 00:12:20,949
And so when you think about what
payviders are offering right now to
207
00:12:20,949 --> 00:12:24,439
the market, they have to be thinking
about how to integrate the pharmacy
208
00:12:24,439 --> 00:12:25,980
benefit into the medical benefit.
209
00:12:26,310 --> 00:12:29,870
And when you say how to integrate it into
the medical benefit, do you mean they
210
00:12:29,870 --> 00:12:33,940
have to be contemplating how they're going
to be doing total cost of care stuff?
211
00:12:34,220 --> 00:12:35,200
Yeah, exactly.
212
00:12:35,280 --> 00:12:38,579
We need to be in a world where
the employer can contract on
213
00:12:38,580 --> 00:12:40,080
the basis of total cost of care.
214
00:12:40,330 --> 00:12:44,289
If I'm a pharma company that's listening
to this right now, there's pharma
215
00:12:44,290 --> 00:12:46,250
companies that have these pipelines.
216
00:12:46,260 --> 00:12:49,360
I'm hearing you say that now we're
going to have provider groups taking
217
00:12:49,360 --> 00:12:53,880
on total cost of care and really
contemplating and having to think
218
00:12:53,890 --> 00:12:57,895
through what the impact is of some
of these drugs that are prescribed.
219
00:12:57,974 --> 00:12:59,685
What's your advice to a pharma company?
220
00:12:59,915 --> 00:13:04,525
Well, look, what I would say is first,
keep innovating because the benefits
221
00:13:04,525 --> 00:13:08,934
of pharmaceutical science are really
driving what is improving medicine today.
222
00:13:09,005 --> 00:13:12,335
And I wouldn't want anything
that I'm going to say to be
223
00:13:12,335 --> 00:13:15,484
mischaracterized as against innovation.
224
00:13:15,525 --> 00:13:21,000
With that said, I think that the cost
of new medications coming to market is
225
00:13:21,010 --> 00:13:25,130
incompatible with our current insurance
system for a couple of reasons.
226
00:13:25,140 --> 00:13:30,310
First, it's just the quantity of
innovation that's coming down the pike.
227
00:13:30,340 --> 00:13:33,730
I don't think we'll be affordable
at current prices to employers.
228
00:13:33,730 --> 00:13:37,819
And we have to be thinking about how to
accommodate the costs into the system.
229
00:13:38,159 --> 00:13:43,389
I'd say also that there is a very strong
interest going forward in figuring out how
230
00:13:43,389 --> 00:13:46,859
to share risk across multiple employers.
231
00:13:46,879 --> 00:13:50,879
We have to figure out ways to share
the risk of these expensive medications
232
00:13:50,949 --> 00:13:53,799
across larger pools of employers.
233
00:13:53,869 --> 00:13:56,989
Otherwise, the employer
based system will not work.
234
00:13:57,479 --> 00:14:01,669
if I'm thinking about this relative
to a pharma company, again, that's
235
00:14:01,669 --> 00:14:06,409
listening here, because, you know,
like, pharma prices that are charged
236
00:14:06,429 --> 00:14:07,759
is kind of the elephant in the room.
237
00:14:07,769 --> 00:14:11,569
Like, we would not even be having
this entire conversation if that
238
00:14:11,569 --> 00:14:13,929
wasn't on the table as a factor here.
239
00:14:14,019 --> 00:14:16,969
Pharmaceutical companies need
to be prepared to contract
240
00:14:16,989 --> 00:14:18,129
on the basis of value.
241
00:14:18,279 --> 00:14:21,309
We haven't seen a lot of
that in the market today.
242
00:14:21,349 --> 00:14:25,169
We've seen a lot of discussion of it,
but if a new cellular therapy comes out.
243
00:14:25,439 --> 00:14:27,719
And it costs 5 million dollars.
244
00:14:27,779 --> 00:14:30,869
The employer is also going to want
to make sure that it doesn't have
245
00:14:30,869 --> 00:14:32,519
to be repeated two years later.
246
00:14:32,679 --> 00:14:37,799
But, like, you don't see very many
pharma companies doing very deeply
247
00:14:37,799 --> 00:14:39,709
collaborative kinds of things.
248
00:14:40,009 --> 00:14:45,129
You know, part of it is being ready
to contract on the basis of value.
249
00:14:45,319 --> 00:14:49,089
Part of it is keeping up with what's
going on in the delivery system.
250
00:14:49,149 --> 00:14:53,679
To date, I think that we've seen a lot of
really excellent medical science come out.
251
00:14:53,839 --> 00:14:54,839
It's been released.
252
00:14:55,089 --> 00:14:59,199
It is paid for on the basis
of how often it's used.
253
00:14:59,499 --> 00:15:03,939
It is not paid for on the basis
of whether it works and what the
254
00:15:03,939 --> 00:15:05,689
value is ultimately to the patient.
255
00:15:06,189 --> 00:15:09,279
And I think therein might
lie one of the rubs.
256
00:15:09,329 --> 00:15:12,229
Just it's really hard to be accountable
for anything if there's no way to
257
00:15:12,229 --> 00:15:14,269
clinically measure what's happening.
258
00:15:14,359 --> 00:15:18,469
Like if a health system, nobody
can even measure the output of
259
00:15:18,549 --> 00:15:20,289
the care that's being delivered.
260
00:15:20,369 --> 00:15:20,659
Yeah.
261
00:15:20,779 --> 00:15:24,549
Rik Renard was like 16 percent of care
flows have any sort of evidence basis.
262
00:15:25,239 --> 00:15:28,389
If you're a pharma company and you're
trying to prove the value of your drug
263
00:15:28,389 --> 00:15:31,989
or try to prove the performance of your
drug, like, that could be a deal breaker.
264
00:15:32,149 --> 00:15:33,359
Yeah, I think that's right.
265
00:15:33,709 --> 00:15:38,334
I think also,
though, for example,
in the GLP-1 class, Many of the
266
00:15:38,334 --> 00:15:43,114
drugs that are coming to market
are essentially forever drugs.
267
00:15:43,244 --> 00:15:45,704
You will be on them forever
once you start them.
268
00:15:45,774 --> 00:15:48,104
And that's the way that
they're being marketed.
269
00:15:48,114 --> 00:15:53,864
There is one product, I believe it is an
Amgen product, where there is a theory
270
00:15:53,914 --> 00:15:59,034
that you would be able to take that GLP-1
for a couple of years, it would change
271
00:15:59,034 --> 00:16:02,284
the signaling in your body, and then
you would be able to go off the drug.
272
00:16:02,604 --> 00:16:05,694
Employers are very interested
in that kind of drug.
273
00:16:06,004 --> 00:16:09,044
The idea of starting on a
therapy and having to pay for it
274
00:16:09,084 --> 00:16:12,904
forever is not as attractive as
being able to cure the patient.
275
00:16:13,254 --> 00:16:17,634
So we've had a very robust conversation
I think around the first point that
276
00:16:17,634 --> 00:16:21,974
you're making and obviously this is
a topic that we probably could have a
277
00:16:22,124 --> 00:16:26,859
college curriculum on which is, have
some kind of value-based component in
278
00:16:26,859 --> 00:16:28,889
the decision making process for pharmacy.
279
00:16:28,939 --> 00:16:30,099
You have to do that.
280
00:16:30,229 --> 00:16:33,329
Otherwise, you're going to
wind up squeezing the balloon.
281
00:16:33,329 --> 00:16:35,229
You're going to have higher medical costs.
282
00:16:35,469 --> 00:16:35,629
Right.
283
00:16:35,909 --> 00:16:39,339
And conversely, drug development
needs to contemplate value.
284
00:16:39,744 --> 00:16:43,284
So, when you think about which
drug is going to be successful in
285
00:16:43,284 --> 00:16:46,114
the market, choose the one that
will bring value to the patient.
286
00:16:46,304 --> 00:16:50,504
And the conversation with Nina
Lathia from several weeks ago,
287
00:16:50,514 --> 00:16:52,094
we did dig into this also.
288
00:16:52,094 --> 00:16:54,704
So if someone's looking for more
information about this, please
289
00:16:54,704 --> 00:16:56,394
go back and listen to that.
290
00:16:56,414 --> 00:16:59,024
The second thing that you talked
about was making sure that we're
291
00:16:59,264 --> 00:17:02,374
engaging the patient in this whole mix.
292
00:17:02,534 --> 00:17:05,344
What was your thinking
when you listed that one?
293
00:17:05,584 --> 00:17:09,724
Well, look, what immediately comes
to mind is Don Berwick's statement,
294
00:17:09,804 --> 00:17:11,494
"Nothing about me without me".
295
00:17:11,704 --> 00:17:14,344
Prescribing has to be done in
consultation with the patient.
296
00:17:14,494 --> 00:17:19,719
And for physicians who are working and
living in a value-based environment,
297
00:17:19,799 --> 00:17:23,589
ultimately their success is
improving the health of populations.
298
00:17:23,589 --> 00:17:27,429
It's really making sure that it's
done in a way that is cost effective
299
00:17:27,429 --> 00:17:30,979
for the patient and ultimately
improves their health outcomes.
300
00:17:31,259 --> 00:17:33,189
Nothing about me without me.
301
00:17:33,289 --> 00:17:34,009
Don Berwick.
302
00:17:34,059 --> 00:17:34,959
Don Berwick.
303
00:17:34,989 --> 00:17:35,229
Yeah.
304
00:17:35,229 --> 00:17:35,819
Gotta love him.
305
00:17:35,889 --> 00:17:36,149
Dr.
306
00:17:36,149 --> 00:17:39,739
Kenny Cole on the show a couple of weeks
ago was talking about just the, you know,
307
00:17:39,849 --> 00:17:42,469
first step is this engagement and trust.
308
00:17:42,479 --> 00:17:45,829
Some of the work that you're doing
with advanced primary care, this
309
00:17:45,839 --> 00:17:48,429
is actually part of the whole gig.
310
00:17:48,449 --> 00:17:52,576
But I would strongly suggest that
probably the ability to pull it
311
00:17:52,576 --> 00:17:55,006
off is limited across the industry.
312
00:17:55,176 --> 00:17:58,896
The engagement piece is something
self insured employers, plan sponsors
313
00:17:58,926 --> 00:18:01,206
really struggle with, number one.
314
00:18:01,266 --> 00:18:04,246
But so do health systems,
for the most part.
315
00:18:04,556 --> 00:18:05,046
I agree.
316
00:18:05,056 --> 00:18:06,256
I agree with what you just said.
317
00:18:06,756 --> 00:18:10,256
If we're thinking about the third
thing, possibly designating a
318
00:18:10,256 --> 00:18:14,576
new pharmacy tier as experimental,
that would have a much higher copay
319
00:18:14,596 --> 00:18:16,256
if there's inadequate evidence.
320
00:18:16,736 --> 00:18:18,936
And you had said let the market work.
321
00:18:19,146 --> 00:18:21,596
Yeah, this is another thing
that employers struggle with.
322
00:18:21,656 --> 00:18:24,876
There are drugs coming to market
with very limited studies.
323
00:18:25,026 --> 00:18:28,646
It's a good thing that these drugs come to
market, but the evidence could be limited.
324
00:18:28,646 --> 00:18:33,686
Or, such as in the case of the GLP-1s,
we have no idea what happens after five
325
00:18:33,686 --> 00:18:37,056
years, but yet there is the expectation
that patients are going to stay on
326
00:18:37,056 --> 00:18:38,836
those drugs for longer than five years.
327
00:18:39,136 --> 00:18:41,686
There are drugs coming to market
that you want them to be on the
328
00:18:41,686 --> 00:18:45,076
market, but you also want to,
you want to be studying them.
329
00:18:45,086 --> 00:18:52,426
So, the idea of approving a drug with
the proviso that it needs to be studied
330
00:18:52,756 --> 00:18:57,746
more extensively I think is ultimately
in the patient's interest and it isn't
331
00:18:57,766 --> 00:19:01,566
a bad thing to designate that with
respect to the formulary so that the
332
00:19:01,646 --> 00:19:04,046
signal can be clear to the patient.
333
00:19:04,106 --> 00:19:09,056
When the drug meets the market,
it should be so designated for the
334
00:19:09,056 --> 00:19:13,136
patient and for the clinician so
that everybody has transparency about
335
00:19:13,336 --> 00:19:15,326
how that drug should be introduced.
336
00:19:15,716 --> 00:19:19,836
And that is a nice follow on
to Nothing About Me Without Me.
337
00:19:20,106 --> 00:19:23,926
Patients are in, a lot of times,
a pickle, or the patient's parent.
338
00:19:24,076 --> 00:19:29,206
They are struggling, they are facing
some really, really difficult news,
339
00:19:29,256 --> 00:19:33,806
and then this drug is introduced,
which potentially could help.
340
00:19:33,806 --> 00:19:36,386
Like a lot of times, you're
going to do anything to try to
341
00:19:36,386 --> 00:19:37,446
figure out how to get that drug.
342
00:19:37,701 --> 00:19:42,081
One of the other issues here is the kinds
of static formularies that we have right
343
00:19:42,081 --> 00:19:46,721
now where you know, you have generic,
you have brand preferred, you have brand
344
00:19:46,721 --> 00:19:52,581
non preferred and specialty do not give
the kind of information and granularity
345
00:19:52,591 --> 00:19:54,801
that patients need to navigate.
346
00:19:54,861 --> 00:20:01,386
The other issue is we might want to be
thinking about how the tiering is giving
347
00:20:01,386 --> 00:20:06,276
incentives to the patient and to the
clinician to produce the optimal outcome.
348
00:20:06,536 --> 00:20:10,326
One of the things that we do in
the JPMorgan Chase formulary is
349
00:20:10,326 --> 00:20:14,996
that preventive drugs are free and
that's kind of a way that we operate
350
00:20:14,996 --> 00:20:18,026
here and if the drug is going to
prevent illness, they are free.
351
00:20:18,026 --> 00:20:23,431
So think about that as kind of an element
of a formulary that ultimately could
352
00:20:23,491 --> 00:20:29,001
be used to bridge the gap between the
pharmacy benefit and the medical side.
353
00:20:29,291 --> 00:20:32,801
That's a really great example
of an understanding that there
354
00:20:32,811 --> 00:20:36,291
is actually some ROI here, or
whatever term you want to use.
355
00:20:36,461 --> 00:20:36,721
Right.
356
00:20:36,741 --> 00:20:38,461
And by the way, that includes insulin.
357
00:20:38,651 --> 00:20:43,286
The idea of putting a big hefty
copay on insulin is crazy.
358
00:20:43,666 --> 00:20:47,286
I mean, Type 1 diabetics
need insulin to live.
359
00:20:47,576 --> 00:20:51,176
Under what theory would
you put a copay on insulin?
360
00:20:51,476 --> 00:20:55,586
That is probably the most
perfect example, or even Type 2.
361
00:20:55,596 --> 00:21:00,096
Like, you know, like, you have a
patient who is prescribed insulin.
362
00:21:00,126 --> 00:21:02,076
Like, how could, how
can you abuse insulin?
363
00:21:02,186 --> 00:21:03,656
The same thing with, like, asthma.
364
00:21:03,916 --> 00:21:07,866
Yeah, it takes you back to the theory
of why do you have cost sharing?
365
00:21:08,086 --> 00:21:10,526
You have cost sharing
to deter utilization.
366
00:21:10,686 --> 00:21:15,236
If you put
cost share on insulin for
a type 1 diabetic, they could die.
367
00:21:15,306 --> 00:21:18,236
And so it doesn't make a lot
of sense to have that coping.
368
00:21:18,236 --> 00:21:22,176
If what you're trying to do is finance
the benefit, do it in a way that does
369
00:21:22,176 --> 00:21:25,196
not incent poor medical behavior.
370
00:21:25,516 --> 00:21:29,256
Well, you bring up an amazing
point there that it's to deter
371
00:21:29,296 --> 00:21:30,586
inappropriate utilization.
372
00:21:30,606 --> 00:21:33,856
This is where initial
intent meets the real world.
373
00:21:33,886 --> 00:21:36,476
And what started to happen
is plan sponsors have
374
00:21:36,476 --> 00:21:37,876
started to try to save money.
375
00:21:38,341 --> 00:21:42,011
In the shortest term way possible, and
if you fundamentally don't understand
376
00:21:42,011 --> 00:21:46,501
that, then just cost containing, across
the board, and just preventing anybody
377
00:21:46,501 --> 00:21:49,701
from getting anything, that seems
like an amazing way to save money.
378
00:21:49,751 --> 00:21:53,301
But yeah, it goes back to what you
were talking about before, that if
379
00:21:53,371 --> 00:21:56,751
pharmaceutical purchasing occurs
in a value-based way, it should
380
00:21:56,781 --> 00:22:00,001
improve outcomes and optimize
or reduce total cost of care.
381
00:22:00,396 --> 00:22:03,786
Right, and the purpose of copays
is to incent patient behavior.
382
00:22:03,786 --> 00:22:07,186
So back to this question of how do
you engage the patient, a lot of
383
00:22:07,186 --> 00:22:09,576
it is through financial incentives.
384
00:22:09,976 --> 00:22:12,786
My issue is that a lot of the
financial incentives that are
385
00:22:12,786 --> 00:22:16,766
layered into formularies today
are the wrong incentives.
386
00:22:16,876 --> 00:22:21,716
They are not incenting good behavior
on the part of the patient and we
387
00:22:21,716 --> 00:22:23,206
have to look really carefully at that.
388
00:22:23,501 --> 00:22:26,131
As they say, the most expensive
drug is the drug sitting in a bottle
389
00:22:26,131 --> 00:22:27,791
that no one's actually taking.
390
00:22:28,051 --> 00:22:33,441
If a drug is paid for, they have an
obligation in a way to take the drug well.
391
00:22:33,741 --> 00:22:36,951
So there is certainly a level
of patient education and
392
00:22:36,951 --> 00:22:38,541
patient engagement and trust.
393
00:22:38,551 --> 00:22:44,301
With the evolution of health information
technology, we will have better ways for
394
00:22:44,321 --> 00:22:49,461
patients and physicians to communicate
about what's in the formulary and
395
00:22:49,541 --> 00:22:51,511
what is the best way to navigate.
396
00:22:51,551 --> 00:22:54,991
And so, you know, in a world where you
didn't have a smartphone, you wouldn't
397
00:22:55,001 --> 00:22:56,341
be able to pull up your formulary.
398
00:22:56,341 --> 00:23:00,621
But now, you can, and that
conversation is going to be had.
399
00:23:01,121 --> 00:23:03,221
The second thing you said was
making sure that we have patient
400
00:23:03,221 --> 00:23:06,091
engagement, and then the third thing
was having this experimental tier.
401
00:23:06,191 --> 00:23:08,711
It seems like you can't have
one without the other, right?
402
00:23:08,711 --> 00:23:12,511
Because if you have this experimental
tier, part of making sure that plan
403
00:23:12,551 --> 00:23:16,951
members are satisfied and know what's
going on there and appreciate it, for
404
00:23:16,951 --> 00:23:20,071
the innovation that it kind of is,
you have to have the communication.
405
00:23:20,431 --> 00:23:24,061
It's tiering that reflects
the incentive that we want the
406
00:23:24,091 --> 00:23:25,671
patient to have around the drug.
407
00:23:25,861 --> 00:23:31,341
We also want to give pharmaceutical
companies strong incentive to bring
408
00:23:31,351 --> 00:23:37,801
information into the public domain that
will enable both employers, clinicians,
409
00:23:37,841 --> 00:23:39,821
and patients to make good decisions.
410
00:23:40,411 --> 00:23:42,931
So, that's kind of the thinking here.
411
00:23:43,151 --> 00:23:46,381
Right now, if you think about
what the FDA requires for
412
00:23:46,381 --> 00:23:48,691
registration, it's a limited subset.
413
00:23:48,871 --> 00:23:53,511
And there's information that I want as
an employer on how the drugs actually
414
00:23:53,511 --> 00:23:58,601
work in populations and subpopulations
that is not required by the FDA.
415
00:23:58,851 --> 00:24:02,921
So, increasing the evidence requirements
I think is really good for everybody.
416
00:24:02,991 --> 00:24:07,001
It's good for the pharmaceutical companies
too because it helps to set a standard
417
00:24:07,311 --> 00:24:09,101
for what kind of information is necessary.
418
00:24:09,541 --> 00:24:13,526
Yeah, and you had mentioned
that in Europe, they have cost
419
00:24:13,536 --> 00:24:17,316
effectiveness evaluations on
different cohorts of subpopulations.
420
00:24:17,326 --> 00:24:21,876
And one of the things that has been
suggested by you and others is to
421
00:24:22,076 --> 00:24:23,866
do that in the United States too.
422
00:24:23,976 --> 00:24:29,316
But this is going to be a culture clash
within pharma companies who maybe in some
423
00:24:29,316 --> 00:24:32,776
cases are a little bit less concerned with
ensuring that the patient is appropriate.
424
00:24:33,056 --> 00:24:36,761
And I think the point that you're making
is If we all want to work together on
425
00:24:36,761 --> 00:24:40,101
this, then making sure that the right
drug is used in the right patient
426
00:24:40,251 --> 00:24:41,831
is going to be really important.
427
00:24:41,861 --> 00:24:47,371
And ultimately, it's to pharma's advantage
to be a part of that moving forward.
428
00:24:47,431 --> 00:24:50,221
Because if the drug is prescribed
to a patient and it doesn't work,
429
00:24:50,221 --> 00:24:52,791
somebody's going to be noticing
that, oh, this drug doesn't
work.
430
00:24:53,261 --> 00:24:53,601
That's right.
431
00:24:53,641 --> 00:24:55,431
We are living in the information age.
432
00:24:55,511 --> 00:24:57,841
Employers see which drugs
work and which ones don't.
433
00:24:58,021 --> 00:25:02,121
I would say also, increasing the flow
of information to employers is in the
434
00:25:02,121 --> 00:25:04,051
pharmaceutical company's best interest.
435
00:25:04,531 --> 00:25:06,801
Because it's the way we want to contract.
436
00:25:06,821 --> 00:25:09,301
Ultimately, we want to
contract on the basis of value.
437
00:25:09,691 --> 00:25:13,351
When you think about the 25 percent
of our spend that is on drugs, we
438
00:25:13,351 --> 00:25:16,971
want to contract for that the same way
that we want to contract for medical
439
00:25:16,971 --> 00:25:18,501
care and we want to integrate it.
440
00:25:18,621 --> 00:25:22,011
And so that's kind of the,
what will be facilitated.
441
00:25:22,021 --> 00:25:26,741
But look, I think that there's a
reluctance to change the bringing
442
00:25:26,741 --> 00:25:28,671
more evidence to the market.
443
00:25:29,096 --> 00:25:33,286
It doesn't change registration or
the commercial launch in any way.
444
00:25:33,286 --> 00:25:37,236
It just gives the consumer
more information about how the
445
00:25:37,236 --> 00:25:38,496
drug works in the real world.
446
00:25:39,006 --> 00:25:42,246
So let me bring up the fourth thing
that you said, which is using more
447
00:25:42,246 --> 00:25:44,576
than just ICER to tabulate value.
448
00:25:44,606 --> 00:25:47,206
And I think you're inching
toward that point right now.
449
00:25:47,706 --> 00:25:52,236
Yeah, ICER has been critically
important for helping the American
450
00:25:52,236 --> 00:25:56,676
health system understand the importance
of the evaluation of drugs and the
451
00:25:56,676 --> 00:26:01,246
importance of bringing that evaluation
forward by a neutral third party.
452
00:26:01,586 --> 00:26:03,286
I think they've done an amazing job.
453
00:26:03,666 --> 00:26:07,156
Steve and Sarah and others
have really pioneered this.
454
00:26:07,541 --> 00:26:11,731
And we're talking about Steve
Pearson, who founded ICER, and Sarah
455
00:26:11,731 --> 00:26:13,421
Emond, who's the current president.
456
00:26:13,501 --> 00:26:16,721
One of the problems is that we only
have ICER, and there should be two or
457
00:26:16,721 --> 00:26:20,671
three similar organizations nationally
that are evaluating the drugs, because
458
00:26:20,671 --> 00:26:25,651
you don't want to just have one group
that bears the brunt of that evaluation.
459
00:26:25,691 --> 00:26:28,481
And by the way, it's a difficult
thing to do, you know, because there
460
00:26:28,481 --> 00:26:31,241
are always going to be financial
interests that are looking at it.
461
00:26:31,466 --> 00:26:33,966
How things are being done and
there will always be criticism.
462
00:26:33,966 --> 00:26:38,936
And so I think we need more ICERs in
the market and we need more information
463
00:26:38,936 --> 00:26:42,836
coming in to enable good decision
making on the part of employers.
464
00:26:43,216 --> 00:26:46,026
Do you think that most employers, you
know, because the one thing that you
465
00:26:46,026 --> 00:26:50,586
often hear if you talk to somebody
in pharma or you talk to many people
466
00:26:50,586 --> 00:26:54,401
across the industry is, well, maybe
there's a vanguard of employers,
467
00:26:54,401 --> 00:26:58,721
but if you're talking about the vast
majority of employers, they're not
468
00:26:58,721 --> 00:27:00,321
paying attention to this kind of thing.
469
00:27:00,321 --> 00:27:05,171
So we should just get while the getting's
good and just wait for the clamp down
470
00:27:05,171 --> 00:27:07,431
to happen because I don't see it coming.
471
00:27:07,896 --> 00:27:13,416
Most employers will appropriately
delegate this responsibility to
472
00:27:13,686 --> 00:27:17,626
their health plan or to a PBM because
they don't have the expertise.
473
00:27:17,676 --> 00:27:21,806
With that said, I think what's going
to happen over the next five years as
474
00:27:21,816 --> 00:27:28,426
more of these incredibly powerful, And
expensive drugs come to market is that
475
00:27:28,446 --> 00:27:32,436
we are going to face an affordability
crisis that will bring employers into
476
00:27:32,436 --> 00:27:34,136
those decisions much more directly.
477
00:27:34,376 --> 00:27:36,406
So it's going to go slow
until it goes real fast?
478
00:27:36,406 --> 00:27:37,356
Is that kind of what you're saying?
479
00:27:38,106 --> 00:27:38,366
Yeah.
480
00:27:38,416 --> 00:27:39,876
I mean, look, cell and gene therapy.
481
00:27:39,876 --> 00:27:40,326
It's coming.
482
00:27:40,326 --> 00:27:40,766
It's here.
483
00:27:41,136 --> 00:27:45,826
The last point that you had talked
about is to consider how far we really
484
00:27:45,826 --> 00:27:48,586
need to micromanage time horizons.
485
00:27:48,926 --> 00:27:52,726
I don't think it makes too much
sense to worry about whether
486
00:27:52,736 --> 00:27:57,266
an employee is with you for two
years, five years, or ten years.
487
00:27:57,306 --> 00:28:00,876
I think that you don't know how long
you're going to have the employee,
488
00:28:00,926 --> 00:28:05,326
and I see a lot of discussion around
what is the appropriate time horizon
489
00:28:05,326 --> 00:28:07,176
for judging cost effectiveness.
490
00:28:07,426 --> 00:28:13,216
So my hope is that we can be thinking
about cost effectiveness over a longer
491
00:28:13,216 --> 00:28:18,066
time horizon so that we can make better
decisions on behalf of the system as
492
00:28:18,066 --> 00:28:22,896
opposed to becoming captive to, you know,
where we are right now, which is kind of
493
00:28:22,906 --> 00:28:24,786
worrying about our own narrow interests.
494
00:28:25,396 --> 00:28:28,996
I want to tie this last point that
you made back to something that you
495
00:28:28,996 --> 00:28:34,736
mentioned at the very top of this
conversation, this whole idea of sharing
496
00:28:34,796 --> 00:28:39,136
across employers, because I just have
a sense that probably this, how are
497
00:28:39,136 --> 00:28:42,646
we going to micromanage time horizons
and the whole, we got to share costs
498
00:28:42,646 --> 00:28:44,626
across employers are probably related.
499
00:28:44,876 --> 00:28:47,266
Pooling of risk is going
to be really important.
500
00:28:47,726 --> 00:28:52,946
In the age of cell and gene therapy, and
we have to figure out a way to pool risk.
501
00:28:53,056 --> 00:28:59,226
The idea that you have relatively small
employers taking financial risk for the
502
00:28:59,226 --> 00:29:02,916
cost of their employees is not going
to be tenable in a world where you want
503
00:29:02,916 --> 00:29:04,586
to be covering cell and gene therapy.
504
00:29:05,016 --> 00:29:09,366
So, thinking about how to do that better
is one of the areas of focus for us.
505
00:29:09,396 --> 00:29:12,316
Chase Bank's about half of the
small businesses in the United
506
00:29:12,316 --> 00:29:13,636
States and we hear from them.
507
00:29:13,866 --> 00:29:18,356
We hear their concerns about healthcare
and the ones that are looking around the
508
00:29:18,366 --> 00:29:23,236
bend are very worried about this idea
and thinking about ways so that they
509
00:29:23,236 --> 00:29:27,126
can protect themselves and still offer
a meaningful benefit to their employees.
510
00:29:27,481 --> 00:29:31,331
Well, let me give another definition
of pulling risk, insurance.
511
00:29:32,501 --> 00:29:32,801
Right.
512
00:29:33,401 --> 00:29:33,921
Yeah.
513
00:29:34,001 --> 00:29:36,191
So are we back where we started?
514
00:29:36,481 --> 00:29:41,301
Yeah, well, you know, look, I think
that many employers appropriately
515
00:29:41,361 --> 00:29:43,341
are trying to keep their costs down.
516
00:29:43,471 --> 00:29:48,201
They go to self insurance because
they reduce administrative costs.
517
00:29:48,611 --> 00:29:49,641
That makes sense.
518
00:29:49,661 --> 00:29:53,951
I think the question is, how can you
pull risk without paying massive risk
519
00:29:53,971 --> 00:29:56,031
premiums to an insurance company?
520
00:29:56,481 --> 00:29:59,496
Is that a rhetorical question or
if I asked you that same question,
521
00:29:59,496 --> 00:30:01,806
how do you pull risk without
going to an insurance company?
522
00:30:01,806 --> 00:30:02,696
Would you have thoughts?
523
00:30:02,756 --> 00:30:03,736
I do have thoughts.
524
00:30:03,736 --> 00:30:04,716
I figured you might.
525
00:30:04,716 --> 00:30:08,616
I think that, look, there's a
reasonable risk premium that can be
526
00:30:08,616 --> 00:30:11,066
applied to cell and gene therapy.
527
00:30:11,216 --> 00:30:13,166
It's not 200 or 300%.
528
00:30:13,866 --> 00:30:19,936
And so, making sure that there is a way
to do this in a way that makes sense is
529
00:30:19,936 --> 00:30:22,096
really in everybody's best interests.
530
00:30:22,571 --> 00:30:27,491
What you're saying is we've got payer
organizations who have consolidated,
531
00:30:27,501 --> 00:30:29,501
there are very few of them.
532
00:30:29,511 --> 00:30:33,461
So therefore we have the whole anti
competitive, whatever you want to call
533
00:30:33,461 --> 00:30:35,521
it, situation in the market today.
534
00:30:35,731 --> 00:30:38,801
You're basically saying that maybe
there's a different way for employers
535
00:30:39,051 --> 00:30:46,371
to solve their own problem themselves
or in a different way than might
536
00:30:46,371 --> 00:30:48,241
be in the market traditionally.
537
00:30:48,641 --> 00:30:53,301
Yeah, we need more innovation
in the provision of benefits
538
00:30:53,311 --> 00:30:54,701
that make sense for employers.
539
00:30:54,751 --> 00:30:58,701
And it will make sense for some
employers to pay a risk premium,
540
00:30:58,701 --> 00:30:59,881
go with a traditional product.
541
00:30:59,891 --> 00:31:00,551
That's fine.
542
00:31:00,651 --> 00:31:04,831
However, increasingly, we're going to see
employers want more value-based products.
543
00:31:04,871 --> 00:31:09,061
What that will mean is narrower
networks, better care navigation,
544
00:31:09,151 --> 00:31:10,911
better integration of pharmacy.
545
00:31:10,931 --> 00:31:10,951
Yeah.
546
00:31:11,556 --> 00:31:15,726
All of the things that Stacey, you
have on your show and are highlighting.
547
00:31:15,776 --> 00:31:17,966
That's the world we
are trying to engineer.
548
00:31:17,996 --> 00:31:22,136
And I think that when you think about
drugs have to fit into that in a way
549
00:31:22,136 --> 00:31:23,406
that makes sense for the employer.
550
00:31:23,916 --> 00:31:25,426
So let's do a lightning round, Dan.
551
00:31:25,426 --> 00:31:25,926
Are you ready?
552
00:31:25,966 --> 00:31:26,126
Yep.
553
00:31:26,146 --> 00:31:29,516
I'm going to name a stakeholder and, you
know, a party in the healthcare industry.
554
00:31:29,526 --> 00:31:33,326
And based on this whole conversation
that we've just had, if you had to just
555
00:31:33,326 --> 00:31:36,716
give one piece of advice or just kind
of like a summary, like this is what
556
00:31:36,716 --> 00:31:38,126
you need to be thinking about right now.
557
00:31:38,126 --> 00:31:39,276
Pharma companies.
558
00:31:39,276 --> 00:31:39,326
Yeah.
559
00:31:39,326 --> 00:31:39,336
Yeah.
560
00:31:39,336 --> 00:31:39,346
Yeah.
561
00:31:39,596 --> 00:31:42,576
I think pharma companies need
to understand that employers are
562
00:31:42,576 --> 00:31:45,866
increasingly going to be contracting
on the basis of value for drugs.
563
00:31:46,096 --> 00:31:49,766
What that means is they need
to be developing drugs in a
564
00:31:49,766 --> 00:31:51,576
way that makes sense for value.
565
00:31:51,646 --> 00:31:55,816
They need to be bringing more
information on value into the healthcare
566
00:31:55,816 --> 00:32:00,706
system and they need to be thinking
about how the locus of prescribing
567
00:32:00,716 --> 00:32:02,696
is
changing in a value-based world.
568
00:32:02,886 --> 00:32:03,986
Hospital systems.
569
00:32:04,236 --> 00:32:08,046
The advice to hospitals is
value-based contracting is coming.
570
00:32:08,471 --> 00:32:13,361
Cost control is important, and when
you look at the value that is being
571
00:32:13,361 --> 00:32:16,381
delivered in a hospital, it's not just
about the cost of the drug, it's about
572
00:32:16,741 --> 00:32:20,491
whether the patient outcome is actually
being achieved in a cost effective way.
573
00:32:20,681 --> 00:32:25,541
So, I would say hospitals are going to
need more information from pharmaceutical
574
00:32:25,541 --> 00:32:27,361
companies about how these products work.
575
00:32:27,731 --> 00:32:33,001
Perform in their environment
and how to increasingly deliver
576
00:32:33,001 --> 00:32:34,911
cost effective care to patients.
577
00:32:35,081 --> 00:32:36,721
That would probably be the
way that I would frame it.
578
00:32:36,821 --> 00:32:40,111
Yeah, and you know, here's the
one thing that I would take away
579
00:32:40,111 --> 00:32:41,361
just from what you just said.
580
00:32:41,581 --> 00:32:48,961
Hospitals better get better at being able
to calculate their own effectiveness.
581
00:32:49,201 --> 00:32:53,251
Because I hear over and over again
from physicians, most notably and most
582
00:32:53,251 --> 00:32:57,521
recently Alex Summers and Jodilyn Owen,
just that they're trying to figure
583
00:32:57,521 --> 00:32:58,781
out that they can't even do a survey.
584
00:32:59,051 --> 00:33:03,921
They just can't get any data relative to
like, how effective are, is this CareFlow?
585
00:33:03,931 --> 00:33:05,401
How effective is this department?
586
00:33:05,661 --> 00:33:08,161
The other thing I'll say about that
clinical environment, I'll probably
587
00:33:08,161 --> 00:33:11,691
regret saying this, but the other thing
I'll say about that clinical environment
588
00:33:11,701 --> 00:33:16,551
is markups on the basis of the cost
of the drug make absolutely no sense.
589
00:33:16,871 --> 00:33:23,421
Why should a cancer center get paid
more for prescribing drug A over
590
00:33:23,421 --> 00:33:25,261
drug B if they do the same thing?
591
00:33:25,561 --> 00:33:27,011
It just makes no sense.
592
00:33:27,131 --> 00:33:28,941
That's the system that we live in today.
593
00:33:29,311 --> 00:33:34,561
So You know, in a value-based world,
buy and bill does not make sense.
594
00:33:34,791 --> 00:33:36,081
We could probably do a whole show on that.
595
00:33:36,281 --> 00:33:38,811
What's your advice to
primary care doctors?
596
00:33:39,091 --> 00:33:44,961
Primary care doctors who are practicing
in the context of a value-based system
597
00:33:45,131 --> 00:33:48,271
are going to need to think about
prescribing on the basis of value.
598
00:33:48,651 --> 00:33:53,661
Primary care doctors need to be
consultative with patients in prescribing.
599
00:33:54,021 --> 00:33:54,301
Got it.
600
00:33:54,341 --> 00:33:56,281
How about entrepreneurs and innovators?
601
00:33:56,661 --> 00:34:01,541
A lot of what we're talking about
requires health system change and
602
00:34:01,891 --> 00:34:04,141
requires better information systems.
603
00:34:04,261 --> 00:34:08,141
There's a huge amount of opportunity to
innovate in all of these different areas.
604
00:34:08,171 --> 00:34:10,591
It's what we look for at Morgan Health.
605
00:34:10,591 --> 00:34:14,081
I would say that it's a lot of
what investors are looking for to
606
00:34:14,081 --> 00:34:16,931
drive better value in health care.
607
00:34:17,171 --> 00:34:18,911
I think it's understandable.
608
00:34:19,201 --> 00:34:24,091
That many investors have not found
good levers into the pharmacy space
609
00:34:24,121 --> 00:34:28,781
at this point, just because of the way
the system is structured and because,
610
00:34:29,071 --> 00:34:33,361
look, when we started Morgan Health,
we decided very consciously to go after
611
00:34:33,431 --> 00:34:37,371
the 75 percent of our costs that were
medical as opposed to the 25 percent
612
00:34:37,796 --> 00:34:42,786
of our costs that were at the pharmacy,
but now we're broadening things out
613
00:34:42,826 --> 00:34:46,986
and thinking about that cost center
and starting to find ways to get in.
614
00:34:47,326 --> 00:34:50,886
Dan Mendelson, thank you so much for
being on Relentless Health Value today.
615
00:34:51,176 --> 00:34:51,976
My pleasure.
616
00:34:52,066 --> 00:34:53,946
I really enjoyed the conversation.
617
00:34:54,006 --> 00:34:54,936
I enjoyed it this time.
618
00:34:54,936 --> 00:34:55,901
I enjoyed it last time.
619
00:34:56,531 --> 00:35:00,151
So let's talk about going over to our
website and typing your email address
620
00:35:00,151 --> 00:35:04,421
in the box to get the weekly email
about the show that has come out.
621
00:35:04,651 --> 00:35:08,941
Sometimes people don't do that because
they have subscribed on iTunes or
622
00:35:08,941 --> 00:35:12,031
Spotify and or we're friends on LinkedIn.
623
00:35:12,691 --> 00:35:19,201
What you get in that email is a full and
unredacted, unedited version of the whole
624
00:35:19,201 --> 00:35:21,391
introduction of the show transcribed.
625
00:35:21,451 --> 00:35:23,121
There's also show notes with timestamps,
626
00:35:23,211 --> 00:35:24,461
Thanks so much for listening.